Meanwhile, univariate analysis in this study suggested that there is a significant difference in PFS between Xuanwei and non-Xuanwei patients with non-small cell lung cancer after first-line treatment with EGFR-TKI, so we performed a subgroup analysis to explore the possible causes of the difference. This evidence concerns the gene EGFR and non-small cell lung carcinoma.